RxDoctor Payments Data

Andrew Nik, MD

Vascular Neurology · Colton, CANPI 1316177520

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 734 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 60 manufacturers reported payments, led by AbbVie at 28.4% of the total.

$13,761in general payments, 2019–2025

Across 734 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$925
  • Acadia Pharmaceuticals Inc$907
  • Supernus Pharmaceuticals, Inc.$823
  • AstraZeneca$583
  • UCB, Inc.$563
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$420%
  • Food & beverage$13,52998%
  • Education$1901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)259$3,911
Biogen55$925
Acadia Pharmaceuticals Inc35$907
Supernus Pharmaceuticals, Inc.49$823
AstraZeneca(2 entities)21$583
UCB, Inc.27$563
SK Life Science, Inc.24$559
Pfizer28$465
Teva Pharmaceuticals USA, Inc.20$404
Biohaven Pharmaceuticals, Inc.20$358
Sunovion Pharmaceuticals Inc.18$329
MDD US Operations, LLC12$314
Lundbeck LLC15$305
Novartis10$225
Amgen(2 entities)8$219
Lilly USA, LLC12$209
Argenx US, Inc.7$173
Avion Pharmaceuticals7$159
Abbott6$133
Corium, LLC5$128
Eisai Inc.6$127
Biohaven Pharmaceutical Holding Company Ltd.7$125
Amneal Pharmaceuticals LLC5$114
Adamas Pharmaceuticals, Inc.5$105
Sanofi5$105
Boston Scientific5$96
Genentech USA, Inc.4$94
Livanova USA, Inc.4$89
Neurelis, Inc.3$86
Harmony Biosciences LLC3$74
Aquestive Therapeutics, Inc.4$68
Greenwich Biosciences, Inc.2$68
Zyla Life Sciences, Inc.4$62
Neurocrine Biosciences, Inc.3$59
Portola Pharmaceuticals, LLC2$57
Kyowa Kirin, Inc.2$48
Upsher-smith Laboratories LLC2$48
Octapharma USA, Inc.2$47
Averitas Pharma Inc.2$45
Acorda Therapeutics, Inc2$42
Otsuka America Pharmaceutical, Inc.2$38
GE HealthCare1$37
Banner Life Sciences, LLC2$35
Jazz Pharmaceuticals Inc.1$35
Johnson & Johnson(2 entities)2$33
Assertio Therapeutics, Inc.2$33
Axsome Therapeutics, Inc.1$29
Merz Pharmaceuticals, LLC1$27
Cycle Pharmaceuticals Inc1$26
Alnylam Pharmaceuticals Inc.1$24
Noctrix Health, Inc.1$24
Tanabe Pharma America, Inc.1$24
Avanir Pharmaceuticals, Inc.1$23
TG Therapeutics, Inc.1$22
Neuropace, Inc.1$19
Aucta Pharmaceuticals, Inc.1$18
Takeda Pharmaceuticals U.S.A., Inc.1$17
Arbor Pharmaceuticals, Inc.1$16
GRT US Holding, Inc.1$14
CSL Behring1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,761 in reported general payments places this provider in the 80th percentile of 58 vascular neurology providers in California.

See all vascular neurology providers in California

Medicare billing

Part B allowed, 2024
$199,023
Medicare patients
602
Services billed
4,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$49,366
UbrelvyUbrogepant34$41,178
AdlarityDonepezil Hcl19$11,500
NeuproRotigotine12$9,587
Memantine Hcl229$9,073
Donepezil Hcl442$5,952
Carbidopa-LevodopaCarbidopa/Levodopa86$4,614
Levetiracetam99$4,399
Pregabalin82$4,267
Memantine Hcl ErMemantine Hcl30$4,072
Lacosamide19$4,005
RivastigmineRivastigmine Tartrate40$2,973
Gabapentin189$2,451
Primidone46$2,370
Quetiapine Fumarate57$2,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$38$49,36620 claims
AbbVieUbrelvy$3,911$41,17834 claims
Corium, LLCAdlarity$128$11,50019 claims
UCB, Inc.Neupro$563$9,58712 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$114$1,41631 claims
Upsher-smith Laboratories LLCTopiramate$48$53220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 vascular neurology providers in California.

Other vascular neurology in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →